Three RCTs (n=1,426) were included in the review.
All of the RCTs were double- or triple-blinded. Two studies reported no loss to follow-up and the third study lost 43 (3%) of its patients to follow-up.
The RBI in survival to admission for vasopressin compared with epinephrine was 20.6% (95% CI: 4.6, 39.3), with an ABI of 5.5% (95% CI: 0.6, 10.4). The NNT to produce one additional survival to admission was 18 (95% CI: 10, 167).
The RBI in survival to discharge for vasopressin compared with epinephrine was 5.8% (95% CI: -21.3, 43.9), with an ABI of 0.6% (95% CI: 0.0, 3.8). The NNT was 167 (95% CI: 26, ∞).
Neurological outcomes were also reported for individual RCTs. No evidence of adverse outcomes was reported. Subgroup data based on treatment course from two of the included studies were also reported.